Results of an ongoing phase 1/2a dose escalation study of HPN424, a tri-specific half-life extended PSMA-targeting T-cell engager, in patients with metastatic castration-resistant prostate cancer (mCRPC).

De Bono, Johann S., Fong, Lawrence, Beer, Tomasz M. · Journal of Clinical Oncology · 2021